drugset / Trial / NCT06073821
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
RandomizedParallel-groupOpen-labelTreatment
Summary
The main objective of this study is to compare the efficacy of sonrotoclax plus zanubrutinib versus venetoclax plus obinutuzumab in participants with chronic lymphocytic leukemia (CLL)
Timeline
- Start
- 2023-11-11
- Primary completion
- 2032-02
- Completion
- 2032-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Obinutuzumab | Monoclonal antibody | 1000 mg | Intravenous |
| Subject | Sonrotoclax | Other / unclassified | — | Oral |
| Comparator | Venetoclax | Small molecule | — | Oral |
| Subject | Zanubrutinib | Small molecule | — | Oral |